Furthermore, emerging evidence in the therapy of obesity highlights the efficacy of newer pharmacological agents, specifically GLP-1 receptor agonists (GLP-1RAs), which significantly reduce body weight, BMI, and waist circumference in patients without diabetes mellitus. This evidence concerns the gene GLP1R and diabetes mellitus.